2023

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Pascall, D. J. et al. (2023) Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. Journal of Infection, 87(2), pp. 128-135. (doi: 10.1016/j.jinf.2023.05.019) (PMID:37270070) (PMCID:PMC10234362)

Liu, X. et al. (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Journal of Infection, 87(1), pp. 18-26. (doi: 10.1016/j.jinf.2023.04.012) (PMID:37085049) (PMCID:PMC10116128)

Pascall, D. J. et al. (2023) The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: a genomics-based retrospective cohort analysis. PLoS ONE, 18(4), e0284187. (doi: 10.1371/journal.pone.0284187) (PMID:37053201) (PMCID:PMC10101505)

2022

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Liu, X. et al. (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. Journal of Infection, 84(6), pp. 795-813. (doi: 10.1016/j.jinf.2022.04.018) (PMID:35405168) (PMCID:PMC8993491)

Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)

2021

Munro, A. P.S. et al. (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 398(10318), pp. 2258-2276. (doi: 10.1016/S0140-6736(21)02717-3) (PMID:34863358) (PMCID:PMC8639161)

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Sullivan, F. et al. (2021) Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), 2000670. (doi: 10.1183/13993003.00670-2020) (PMID:32732334)

2015

Thomson, N. C., Chaudhuri, R. , Spears, M., Haughney, J. and McSharry, C. (2015) Serum periostin in smokers and never smokers with asthma. Respiratory Medicine, 109(6), pp. 708-715. (doi: 10.1016/j.rmed.2015.03.009) (PMID:PMID:25869)

Articles

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Pascall, D. J. et al. (2023) Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. Journal of Infection, 87(2), pp. 128-135. (doi: 10.1016/j.jinf.2023.05.019) (PMID:37270070) (PMCID:PMC10234362)

Liu, X. et al. (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Journal of Infection, 87(1), pp. 18-26. (doi: 10.1016/j.jinf.2023.04.012) (PMID:37085049) (PMCID:PMC10116128)

Pascall, D. J. et al. (2023) The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: a genomics-based retrospective cohort analysis. PLoS ONE, 18(4), e0284187. (doi: 10.1371/journal.pone.0284187) (PMID:37053201) (PMCID:PMC10101505)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Liu, X. et al. (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. Journal of Infection, 84(6), pp. 795-813. (doi: 10.1016/j.jinf.2022.04.018) (PMID:35405168) (PMCID:PMC8993491)

Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)

Munro, A. P.S. et al. (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 398(10318), pp. 2258-2276. (doi: 10.1016/S0140-6736(21)02717-3) (PMID:34863358) (PMCID:PMC8639161)

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Sullivan, F. et al. (2021) Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), 2000670. (doi: 10.1183/13993003.00670-2020) (PMID:32732334)

Thomson, N. C., Chaudhuri, R. , Spears, M., Haughney, J. and McSharry, C. (2015) Serum periostin in smokers and never smokers with asthma. Respiratory Medicine, 109(6), pp. 708-715. (doi: 10.1016/j.rmed.2015.03.009) (PMID:PMID:25869)